Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 12/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063638 | 0.88 | MAP2K4 (0.50) | MAP2K4MAP2K7TRPA1LRRK2IDO1 | |
| SCHEMBL4059673 | 0.88 | MAP2K4 (0.62) | MAP2K4MAP2K7TRPA1LRRK2IDO1 | |
| SCHEMBL4061854 | 0.86 | MAP2K4 (0.48) | MAP2K4MAP2K7LRRK2MAPK8MAPK10 | |
| SCHEMBL4058556 | 0.85 | MAP2K4 (0.59) | MAP2K4MAP2K7TRPA1JAK2LRRK2 | |
| SCHEMBL4060826 | 0.85 | MAP2K4 (0.49) | MAP2K4MAP2K7MAPK8MAPK10MAPK14 | |
| SCHEMBL4061642 | 0.82 | MAP2K4 (0.43) | MAP2K4TRPA1JAK2LRRK2IDO1 | |
| SCHEMBL4058171 | 0.82 | MAP2K4 (0.52) | MAP2K4MAP2K7LRRK2MAPK8MAPK10 | |
| SCHEMBL4065232 | 0.82 | MAP2K4 (0.48) | MAP2K4TRPA1LRRK2MAPK8MAPK10 | |
| SCHEMBL4059067 | 0.81 | MAP2K4 (0.50) | MAP2K4MAP2K7TRPA1LRRK2MAPK1 | |
| SCHEMBL4063919 | 0.81 | MAP2K4 (0.50) | MAP2K4MAP2K7TRPA1LRRK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | claimed |
| EP-1747202-A1 | INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-31 | — | — | EP | claimed |
| US-20050215595-A1 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-29 | — | — | US | claimed |
| WO-2005085206-A1 | INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | claimed |
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20050215595-A1 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215595-A1 | Indazole derivatives and methods for using the same | MAPK1, MAP3K1, MAP3K7 | MAP2K4 73/4885MAP2K7 37/4885TRPA1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.